Diamond mouse model is latest in a string of nonclinical studies confirming the antifibrotic effects of hepion pharmaceutical's lead drug, crv431

Edison, n.j., march 23, 2021 (globe newswire) -- hepion pharmaceuticals, inc. (nasdaq:hepa, “hepion”), a clinical stage biopharmaceutical company focused on artificial intelligence (“ai”) - driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“nash”) and liver disease, today announced positive results from an in vivo study of crv431 in a diet-induced animal model of non-alcoholic fatty liver disease (“diamond”).1
HEPA Ratings Summary
HEPA Quant Ranking